Related Experiment Video
Updated: Dec 23, 2025
05:52
Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy
Published on: October 28, 2022
964
Topiramate for hypoxic ischemic encephalopathy: A systematic review protocol.
Guoming Chen1, Yijun Chen2,3, Yaying Xie1
1Guangzhou University of Chinese Medicine.
Medicine
|April 26, 2020
Summary
Topiramate (TPM) may effectively reduce seizure activity in neonatal hypoxic-ischemic encephalopathy (HIE). This systematic review will assess TPM
Area of Science:
- Neonatal neurology
- Neurocritical care
- Pharmacology
Background:
- Hypoxic-ischemic encephalopathy (HIE) is a significant cause of neonatal brain injury.
- Current treatments for HIE have limitations and some mechanisms remain unclear.
- Topiramate (TPM) is an off-label anticonvulsant used for neonatal HIE seizures.
Purpose of the Study:
- To evaluate the efficacy and safety of Topiramate (TPM) for treating neonatal hypoxic-ischemic encephalopathy (HIE).
- To synthesize existing evidence on TPM's therapeutic effects in HIE patients.
Main Methods:
- Systematic literature search across eight databases (PubMed, Cochrane Library, Embase, Web of Science, CNKI, CBM, Wang Fang, VIP) up to 2019.
- Meta-analysis of included studies using RevMan V5.3, assessing primary outcomes via neonatal behavioral neurological assessment.
- Cochrane risk of bias tool for quality appraisal; random or fixed effects models based on heterogeneity.
Main Results:
- This study is expected to provide current evidence on Topiramate's role in reducing seizure activity associated with HIE.
- The findings will focus on the effectiveness of TPM as an intervention for HIE.
Conclusions:
- This review aims to determine the effectiveness and safety of Topiramate (TPM) in the treatment of hypoxic-ischemic encephalopathy (HIE).
- Results will inform clinical practice regarding the use of TPM for HIE.
